What do we really know about antibiotic pharmacodynamics?

Pharmacotherapy

Volumn 21, Issue 11 II, 2001, Pages

  Gunderson, B W ^a   Ross, G H ^a   Ibrahim, K H ^a   Rotschafer, J C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFALORIDINE; CEFALOTIN; CEFAZOLIN; CEFMENOXIME; CEFTAZIDIME; CEFTIBUTEN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ENOXACIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; NETILMICIN; OFLOXACIN; PENICILLIN G; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; SIDE EFFECT;

EID: 0034755694     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.18.302s.33905     Document Type: Conference Paper

References (100)

1. Effect of schedule of administration on the therapeutic efficacy of penicillin
2. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity
3. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models
4. In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli
5. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats
6. Experimental infection with Streptococcus pneumoniae in mice: Correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins
7. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis
8. Bactericidal activity of cephalosporins in an in vitro model simulating serum levels
9. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
10. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections
11. Role for dual individualization with cefmenoxime
12. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
13. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model
14. Influence of four modes of administration on penetration of aztreonam, cefuroxime, and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzae
15. The pharmacodynamics of β-lactams
16. Treatment of gram-negative bacillary septicemia with cefoperazone
17. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients
18. High-dose penicillin therapy and pneumococcal pneumonia
19. Continuous infusion of β-lactam antibiotics
20. Choosing an antibiotic on the basis of pharmacodynamics
21. Pharmacodynamics of ampicillinsul-bactam in an in vitro infection model against Escherichia coli strains with various levels of resistance
22. Efficacy of beta-lactam antibiotics: Integration of pharmacokinetics and pharmacodynamics
23. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis
24. Differences in time above MIC (T>MIC) required for efficacy of β-lactams in animal model infections
25. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
26. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
27. Comparison of gentamicin dosing regimens using an in vitro model
28. Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic
29. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing
30. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia
31. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
32. Adaptive resistance to aminoglycoside antibiotics from firstexposure down-regulation
33. Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin
34. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia
35. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia
36. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis
37. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides
38. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
39. Gentamicin pharmacokinetics in 1,640 patients: Method for control of serum concentrations
40. Single daily dosing of aminoglycosides: A commentary
41. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model
42. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use
43. Once-daily aminoglycoside therapy
44. Pharmacodynamic factors of antibiotic efficacy
45. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: Effect of simultaneous versus staggered administration in an in vitro model of infection
46. Twenty-four hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model
47. In vitro evaluation of pharmacodynamic outcome parameters for three fluoroquinolones against Streptococcus pneumoniae
48. Levofloxacin pharmacodvnamics vs Streptococcus pneumoniae
49. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
50. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
51. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
52. Investigation of AUC/MIC ratio as a generic predictor of fluoroquinolone activity against Staphylococcus aureus using trovafloxacin, ciprofloxacin, sparfloxacin, and levofloxacin in an in vitro pharmacodynamic model
53. Evaluation of the activity of the newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae
54. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model
55. Pharmacodynamic outcome parameters as predictors for fluoroquinolones in the treatment of anaerobic infections
56. Fluoroquinolone pharmacodynamics in Bacteroides thetaiotamicron
57. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
58. In vivo pharmacodynamic activity of sitafloxacin against multiple bacterial pathogens
59. In vivo pharmacodynamic activity of gatifloxacin against multiple bacterial pathogens
60. In vivo pharmacodynamic activity of gemifloxacin against multiple bacterial pathogens
61. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar
62. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
63. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
64. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
65. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
66. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections
67. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure
68. Pharmacodynamics (PDs) of oral OPC-17116 in patients (pts) with acute bacterial exacerbations of chronic bronchitis
69. Pharmacodynamic comparison of clarithromycin vs erythromycin
70. In vivo and in vitro postantibiotic effects (PAEs) of azithromycin
71. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions
72. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection
73. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis
74. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection
75. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions
76. Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin
77. Pharmacokinetics and pharmacodynamics of newer macrolides
78. Postantibiotic effects and the dosing of macrolides, azalides and streptogramins
79. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection
80. Vancomycin
81. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe relationship between concentration and pharmacodynamic response
82. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for treatment of Staphylococcus aureus endocarditis in rats and role of conditions in this determination
83. Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model
84. Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus with and without a raised MBC evaluated by two methods
85. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via timekill-curve and postantibiotic effect methods
86. Critical influence of resistance to streptogramin B-type antibiotics activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus
87. Bactericidal activity of semisynthetic streptogramin RP 59500 against S. aureus
88. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
89. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion
90. Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis
91. Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa
92. Pharmacodynamics of β-lactam antibiotics on gram-negative bacteria: Initial killing, morphology and postantibiotic effect
93. Antibiotic pharmacodynamics in cerebrospinal fluid
94. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones
95. Antimicrobial action and pharmacokinetics/pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance
96. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance
97. Decreased susceptibility of anaerobic gram-negative bacteria to trovafloxacin
98. Human pharmacodynamics of β-lactams, aminoglycosides and their combination
99. Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model
100. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model